Negative
●
Proactive Investors
●
about 2 months ago
Novo Nordisk (NYSE:NVO) pulled back the curtain on its future at an investor day in London, and the audience filed out distinctly underwhelmed. The Danish drugs giant, best known for the weight-loss sensation Wegovy, used its biennial capital markets day to explain how it will thrive once its blockbuster obesity drugs lose patent protection.